Logo image of GLMD

GALMED PHARMACEUTICALS LTD (GLMD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GLMD - IL0011313900 - Common Stock

1.05 USD
+0.02 (+1.94%)
Last: 12/12/2025, 8:00:01 PM
1.02 USD
-0.03 (-2.86%)
After Hours: 12/12/2025, 8:00:01 PM
Fundamental Rating

2

GLMD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. GLMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GLMD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GLMD has reported negative net income.
In the past year GLMD has reported a negative cash flow from operations.
GLMD had negative earnings in each of the past 5 years.
In the past 5 years GLMD always reported negative operating cash flow.
GLMD Yearly Net Income VS EBIT VS OCF VS FCFGLMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -40.31%, GLMD perfoms like the industry average, outperforming 58.95% of the companies in the same industry.
The Return On Equity of GLMD (-45.52%) is better than 67.98% of its industry peers.
Industry RankSector Rank
ROA -40.31%
ROE -45.52%
ROIC N/A
ROA(3y)-63.37%
ROA(5y)-66.75%
ROE(3y)-76.34%
ROE(5y)-80.13%
ROIC(3y)N/A
ROIC(5y)N/A
GLMD Yearly ROA, ROE, ROICGLMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

GLMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLMD Yearly Profit, Operating, Gross MarginsGLMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

6

2. Health

2.1 Basic Checks

GLMD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for GLMD has been increased compared to 5 years ago.
GLMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GLMD Yearly Shares OutstandingGLMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
GLMD Yearly Total Debt VS Total AssetsGLMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -11.70, we must say that GLMD is in the distress zone and has some risk of bankruptcy.
GLMD has a worse Altman-Z score (-11.70) than 76.65% of its industry peers.
GLMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.7
ROIC/WACCN/A
WACCN/A
GLMD Yearly LT Debt VS Equity VS FCFGLMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 7.98 indicates that GLMD has no problem at all paying its short term obligations.
The Current ratio of GLMD (7.98) is better than 73.82% of its industry peers.
GLMD has a Quick Ratio of 7.98. This indicates that GLMD is financially healthy and has no problem in meeting its short term obligations.
GLMD has a better Quick ratio (7.98) than 73.82% of its industry peers.
Industry RankSector Rank
Current Ratio 7.98
Quick Ratio 7.98
GLMD Yearly Current Assets VS Current LiabilitesGLMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

GLMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 85.12%, which is quite impressive.
EPS 1Y (TTM)85.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

GLMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.74% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-79.07%
EPS Next 2Y15.81%
EPS Next 3Y16.31%
EPS Next 5Y20.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GLMD Yearly Revenue VS EstimatesGLMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2029 2030 10M 20M 30M 40M
GLMD Yearly EPS VS EstimatesGLMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150 -200 -250

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GLMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GLMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLMD Price Earnings VS Forward Price EarningsGLMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLMD Per share dataGLMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as GLMD's earnings are expected to grow with 16.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.81%
EPS Next 3Y16.31%

More info and screens

0

5. Dividend

5.1 Amount

GLMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALMED PHARMACEUTICALS LTD

NASDAQ:GLMD (12/12/2025, 8:00:01 PM)

After market: 1.02 -0.03 (-2.86%)

1.05

+0.02 (+1.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-26 2025-11-26/bmo
Earnings (Next)03-31 2026-03-31/amc
Inst Owners1.04%
Inst Owner Change-4.16%
Ins Owners0.92%
Ins Owner ChangeN/A
Market Cap7.50M
Revenue(TTM)N/A
Net Income(TTM)-8.70M
Analysts43.33
Price TargetN/A
Short Float %0.02%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.84%
Min EPS beat(2)25.58%
Max EPS beat(2)40.09%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)32%
EPS NQ rev (3m)32%
EPS NY rev (1m)29.14%
EPS NY rev (3m)29.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB 0.39
EV/EBITDA N/A
EPS(TTM)-3.6
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0
BVpS2.68
TBVpS2.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.31%
ROE -45.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-63.37%
ROA(5y)-66.75%
ROE(3y)-76.34%
ROE(5y)-80.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.98
Quick Ratio 7.98
Altman-Z -11.7
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.98%
EPS Next Y-79.07%
EPS Next 2Y15.81%
EPS Next 3Y16.31%
EPS Next 5Y20.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y31.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.54%
OCF growth 3YN/A
OCF growth 5YN/A

GALMED PHARMACEUTICALS LTD / GLMD FAQ

What is the fundamental rating for GLMD stock?

ChartMill assigns a fundamental rating of 2 / 10 to GLMD.


Can you provide the valuation status for GALMED PHARMACEUTICALS LTD?

ChartMill assigns a valuation rating of 0 / 10 to GALMED PHARMACEUTICALS LTD (GLMD). This can be considered as Overvalued.


How profitable is GALMED PHARMACEUTICALS LTD (GLMD) stock?

GALMED PHARMACEUTICALS LTD (GLMD) has a profitability rating of 1 / 10.


How financially healthy is GALMED PHARMACEUTICALS LTD?

The financial health rating of GALMED PHARMACEUTICALS LTD (GLMD) is 6 / 10.


Can you provide the expected EPS growth for GLMD stock?

The Earnings per Share (EPS) of GALMED PHARMACEUTICALS LTD (GLMD) is expected to decline by -79.07% in the next year.